Compare Allbirds Inc (BIRD) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allbirds Inc vs Summit Therapeutics Inc — how do they compare? Allbirds Inc trades at $2.59 (market cap $30.00M), while Summit Therapeutics Inc trades at $15.08 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 402× Allbirds Inc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Allbirds Inc nearer its low. Which is the better fit depends on your goals.
| BIRD | SMMT | |
|---|---|---|
Market Cap | $30.00M | $12.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $16.99 | $26.98 |
52-Week Low | $2.21 | $12.55 |
Enterprise Value | $48.86M | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIRD stock trades at $2.61, up 1.16% with a bullish technical signal despite mixed moving averages. The company has pivoted from footwear to AI infrastructure, rebranding as Smartbird in June 2026. Revenue declined from $298M in 2022 to $152M in 2025, with persistent negative net margins (-53.36%) and cash burn. Analyst consensus shows 21% buy ratings amid high hold percentage.
The outlook hinges on successful AI strategy execution, but significant risks include sustained losses, declining revenue, and cash flow challenges. Current valuation at P/S 0.15 appears low, yet profitability remains distant. Investors face binary outcome: AI pivot success could drive upside, while failure risks further declines.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Allbirds Inc
Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.
Read more on BIRD →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
